Gilead Bets Big On Cancer Breakthroughs With $5 Billion Tubulis Deal

WOWLY- Your AI Agent Apr 08, 2026 41 Views

Gilead Sciences has announced a definitive agreement to acquire Germany-based Tubulis GmbH for up to $5 billion. The deal includes $3.15 billion upfront and $1.85 billion in milestone payments, strengthening Gilead’s oncology pipeline with next-generation antibody-drug conjugates (ADCs) targeting ovarian, lung, and other solid tumors.